NOVO NORDISK A/S
Bagsværd, Denmark, 3 November 2014 - Today, Novo Nordisk launches NovoRapid® PumpCart®, the first prefilled pump cartridge with an insulin analogue that has been specifically designed for insulin pumps. This new treatment solution, which contains NovoRapid® (insulin aspart) - a rapid-acting insulin from Novo Nordisk - is expected to make insulin pump therapy more convenient for people with diabetes and their care staff. The 1.6 ml cartridge is developed in a non-exclusive partnership between Roche Diabetes Care and Novo Nordisk and is compatible with the new Accu-Chek® Insight insulin pump therapy system from Roche Diabetes Care.
"One of the challenges in operating a traditional pump lies in the manual filling of the insulin reservoir, a procedure with multiple steps, which can often be perceived as a complex and time-consuming process by patients and healthcare professionals alike," commented Dr Parth Narendran, clinical senior lecturer and honorary consultant in medicine at the University of Birmingham.
He continued: "This can be a difficult hurdle to overcome when starting on insulin pump therapy, and is exacerbated by the extensive amount of time needed by healthcare staff to provide the necessary support during pump initiation. A simpler process could address this issue and deliver tangible benefits for those patients who rely on insulin pump therapy every day to manage their diabetes."
Compared to multiple daily injections, insulin pumps can provide greater flexibility of lifestyle and potentially tighter blood glucose control without an increased risk of hypoglycaemia.1-2
"This can provide benefits to certain patients," explained Dr Mark Evans, lecturer and honorary consultant in medicine at the University of Cambridge. "In Europe, we've seen a slow but steady increase in insulin pump therapy uptake in recent years, but there is still room for improvement; in the United Kingdom pumps are currently used by 19% of
children and 6% of adults with type 1 diabetes."
Corporate Communications
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet: www.novonordisk.com CVR no:
24 25 67 90
ZINC ID#: HQMMA/NR/1014/0187
Date of Approval: October 2014
Page 2 of 3
NovoRapid® PumpCart® is being launched in the UK, Sweden and Austria today and will be made available in more European countries throughout 2015 and 2016. The Accu- Chek® Insight insulin pump therapy system has been launched in Austria in the first half of this year and is being launched in the UK today, with other European markets following throughout 2015.
About Insulin Pump TherapyAn insulin pump delivers insulin from a reservoir inside the pump to a patient's body using an infusion set and a tiny cannula. Insulin pumps use fast-acting insulin such as insulin aspart. The insulin is delivered using continuous infusion and is often used by people with type 1 diabetes who receive intensified insulin therapy and test their blood glucose levels on a regular basis. An insulin pump is suitable for certain patients and provides more flexibility, with the potential to improve glycaemic control and quality of life1-2. In Europe, use of insulin pumps among people with type 1 diabetes varies with less than 5% using a pump in some countries to more than 15% in other countries. In the US, 40% are treated with insulin from a pump3.
About NovoRapid®
NovoRapid® (insulin aspart) is a mealtime insulin analogue indicated for the treatment of
diabetes mellitus in adults, adolescents, children aged 2 years and above and can be used in pregnancy. NovoRapid® has been available for use in Europe since 1999 and is approved in more than 100 countries.
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately
40,700 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk.com
Further informationMedia, Novo Nordisk: | ||
Katrine Sperling | +45 4442 6718 | krsp@novonordisk.com |
Media, Roche Diabetes Care: Ute Volkmann | +49 621 759 9561 | ute.volkmann@roche.com |
Investors: | ||
Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com |
Jannick Lindegaard Denholt | +45 3079 8519 | jlis@novonordisk.com |
Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com |
Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com |
Novo Nordisk A/S
Corporate Communications
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet: www.novonordisk.com CVR no:
24 25 67 90
ZINC ID#: HQMMA/NR/1014/0187
Date of Approval: October 2014
Page 3 of 3
Al/ trademarks used or mentioned in this release are /egally protected.
References:l. Cohen ND, et al. Diabetes Technol Ther. 2013;15:544-9.
2. Pickup JC. Nat Rev Endocrino/. 2012;8:425-33.
3. Pickup JC. Insulin pumps. Int J Clin Pract. 2011;65(Suppl.170):16-19.
Nova N ordisk A/S Corporate Comm unications
Nova Allé
2880 Ba gsvaerd
Denma rk
Te leph on e:
+45 4444 8888
Internet : www.novonordisk.com CVR no:
24 25 67 90
ZINC ID#: HQMMA/NR/1014/0187
Date of Approva i: October 2014
|
distributed by
|
